Anu Balendran, Ph.D., was appointed VP Business Development at Alligator Bioscience.
CVS Health introduced Transform Rheumatoid Arthritis Care to help the company’s pharmacy benefit management clients better manage care and costs for rheumatoid arthritis. The program is the latest addition to the company’s suite of condition-specific, highly personalized Transform Care programs and adds value-based management strategies including outcomes-based contracts and a new indication-based formulary for autoimmune conditions to CVS Health’s integrated pharmacy care model
As part of its CareCentered Contracting program, pharmacy benefit manager Prime Therapeutics LLC entered into an outcomes-based contract with Boehringer Ingelheim for Jardiance, an oral type 2 diabetes medicine indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
The FDA granted the De Novo request for the commercialization of Banyan BTITM (Brain Trauma Indicator), an in vitro diagnostic blood test to aid in the evaluation of patients with suspected TBI, also known as concussion.
CMI/Compas promoted two leaders into EVP, Managing Director roles: Elizabeth Barron and Justin Freid.
McCann Health announced the appointment of Daniel Carucci, MD, MSc, PhD, to the new position of Global Medical Director.
Pfizer Inc.’s once-daily oral Janus kinase 1 (JAK1) inhibitor PF-04965842 received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the treatment of patients with moderate-to-severe atopic dermatitis.
The EC approved Herzuma for patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have HER2 overexpression or HER2 gene amplification.
Eisai Co. Ltd. announced that the results of a Phase III study of its in-house discovered and developed anticancer agent lenvatinib mesylate in patients with hepatocellular carcinoma were published in the online version of The Lancet.